INTRODUCTION
Drug blood concentrations have been used to individualize drug dosing because many drugs, including calcineurine inhibiting immunosuppressant drugs like tacrolimus (Tacro), exhibit large interindividual pharmacokinetic and pharmacodynamic (PD) differences. [1] [2] [3] [4] In solid organ transplantation, dosing of calcineurine inhibiting immunosuppressant drugs is adjusted on the basis of published therapeutic ranges (TRs). These TRs were established by consensus groups 3 based on studies that statistically compared various outcomes (eg, rejection, graft survival, or toxicity) in groups of patients enrolled in randomized controlled trials 3, [5] [6] [7] with various measures of drug exposure (eg, trough Tacro concentrations). Dosing of liver transplantation (LTx) patients who were enrolled in these trials was adjusted based either on preselected Tacro concentration ranges or on surrogate biomarkers, such as liver enzymes, because until now no studies have demonstrated good correlation between PD markers and immunosuppressant efficacy, 2, 8 and there have been no practical biomarkers available that directly and specifically measure organ integrity. These Tacro TRs, although useful to establish general concentration targets that improve patient and graft survival, 9 are imprecise, vary from center to center, and have limitations for managing individual patients. 1, 3, 8, 10 There are differences between various recommended trough Tacro TRs and the trough Tacro concentrations needed in individual LTx patients to prevent rejection while avoiding the complications of excessive immune suppression (eg, renal damage or infections). 1, 8, 10 These individual differences are the result of many variables, including pharmacokinetic/PD differences in the recipients and in the Tacro assays used, the degree of donor/recipient match, the quality of the graft, other drugs and surgical procedures used, and the time after LTx. 2, 3, 8 A discussion of these differences is beyond the scope of this brief report.
In addition, previously, graft integrity has been measured only indirectly using conventional liver tests, such as alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, g-glutamyltransferase, and bilirubin, which are not diagnostic of acute cellular rejection. 9 Although complicated and expensive DNA sequencing methods were recently reported to be able to assess graft integrity, 11 these methods were both very expensive and too time consuming to be clinically useful for LTx patient monitoring. However, recently, it has become possible at a reasonable cost to rapidly (within 1 day) and directly assess graft integrity by specifically measuring the percentage of plasma circulating GcfDNA in relation to that from the recipient. This technology, although not yet commercially available, has been shown to identify both the early rejection and the vascular causes of graft damage. 12 This technique is being investigated in a large prospective multicenter study designed to identify ways to individualize treatment after solid organ (heart, kidney, and liver) transplantation. As part of these studies, we evaluated whether organ integrity measured by GcfDNA could be used to reexamine minimally effective trough Tacro concentrations in adult LTx patients, which is the basis of the data presented here.
MATERIALS AND METHODS
The studies described were approved by the local ethics committees. Briefly, adult organ transplant patients who gave their informed consent before LTx had blood samples collected at intervals after transplantation.
Data presented here are from 10 of the first 14 adult LTx patients who gave their consent to be studied. Data are not included from 3 hepatitis C virus (HCV) negative patients (1 woman aged 22 years and 2 men aged 47 and 57 years) who died before any samples were obtained and from a fourth subject (man, aged 62 years, retransplanted, hepatitis B positive) who was excluded on the basis of multiple factors, including but not limited to the collection of nontrough Tacro concentrations, the use of extracorporeal support for extremely high (.40 mg/dL) bilirubin levels, use of unusually large amounts of biologic products (albumin, clotting factors, and transfusions) likely to contain extraneous DNA, and failure to be treated with the same drug regimen as the other 13 subjects. All the remaining 10 patients received immunosuppressant drugs as per the protocol used in Goettingen (available on request) that includes basiliximab, methylprednisolone, and mycophenolate mofetil in addition to Tacro. The 10 subjects were all white and included 3 HCV+ patients and 8 men with a mean 6 SD age of 56 6 9.4 years ( Table 1) .
A total of 103 paired Tacro and GcfDNA measurements from samples collected between days 5 and 30 after LTx were analyzed. Special DNA collection tubes were used as previously described. 12 Trough Tacro concentrations were measured using a published LC-MS/MS method 13 using a Quattro Premier XE Mass Spectrometer (Waters) by the University Medical Center Goettingen laboratory that is a regular participant in an external immunosuppressant drug quality control program.
GcfDNA was measured by the laboratory of Chronix Biomedical, Goettingen, Germany, using the proprietary, published droplet digital polymerase chain reaction (ddPCR) assay 12 that uses selected single nucleotide polymorphisms (SNPs) to differentiate between donor and graft DNA isolated from plasma samples. Each subject had individualized ddPCR tests used to monitor GcfDNA percentages over time. In brief, for each patient, those SNP assays that allowed differentiation were selected using conventional real-time allele detection from a total of 41 SNP assays. Using those SNPs, the percentage of graft cfDNA was subsequently quantified by means of ddPCR in a QX100 system (Bio-Rad), as previously described. 12 The imprecision of the GcfDNA assay was ,15% even with low (2%) GcfDNA percentages.
A GcfDNA of 10% or less was set as indicating organ integrity because this is the percentage that was associated with good graft function in a different group of long-term, stable LTx subjects (n = 10) with no signs of rejection described elsewhere. 12 The number of samples with GcfDNA above and below 10% were categorized for patients whose simultaneous trough Tacro concentrations were below versus those that were above the lower limit of the TR (8 mg/L) used by the transplant surgeons at our institution to adjust Tacro dosing during the first 6 weeks after LTx. The statistical difference of the distribution into the 4 emerging categories was determined using the Fisher exact test. Comparisons were also made using the Youden index [u (Tacro $ delimiterjGcfDNA , 10) + u (Tacro $ delimiterjGcfDNA $ 10)21] and the 2log Fisher P values to define the best lower limit of the Tacro TR at 0.1 mg/L intervals using a receiver operator characteristic curve method. The area under the curve of the receiver operator characteristic curve was calculated by the trapezoidal rule with 95% confidence interval (CI).
14 To eliminate artificial peaks because of ties, the Youden and Fisher values were subjected to a Parzen-Rosenblatt 15, 16 smoothing (s 2 = 0.5, i = 3). 
RESULTS
Although individual subjects had some differences in their minimum effective Tacro concentration, for the entire group, there was a highly significant segregation (Fisher P = 0.00002) in these 103 Tacro/GcfDNA pairs between trough Tacro concentrations that were below the target concentration used in our institution during the first 6 weeks after LTx (8-12 mg/L) 3 and GcfDNA below 10% (Fig. 1 ). All but 2 samples from 7 HCV2 patients had ,10% GcfDNA when trough Tacro concentrations were within the range of 8-12 mg/L, and these 2 exceptions were associated with only minor (ie, ,15%) elevations of GcfDNA. The 3 HCV+ subjects had more variable results. The Tacro dosages aiming for through Tacro concentrations in the TR were highly variable (Fig. 2) , supporting the necessity for therapeutic drug monitoring.
The area under the curve of the receiver operator characteristic curve yielded its maximum (0.83; 95% CI, 0.67-0.93, P , 10 25 ) at a segregating value of 10% GcfDNA (Fig. 3) . The 10% limit for GcfDNA had been chosen based on the data from a separate group of chronically stable adult LTx patients without clinical evidence of any complications during their post-LTx follow-up. 12 Simulations with the dataset given here proved that this tentative limit gives the best separation for the evaluation of effective Tacro concentrations. This supports the decision to use 10% GcfDNA as the limit to define LTx graft integrity.
The maximally effective minimum concentration in this group of subjects (n = 10) seemed to be 6.8 mg/L as defined by a maximized Youden index of 0.51 and the peak 2log Fisher P of 6.9 (Fig. 3) . The odds ratio at this Tacro concentration boundary was 10.7 (CI 95 , 4.2-27.1). This translates for the patients in this dataset into a 4-fold (CI 95 , 2.2-7.2) relative risk of having graft damage (ie, GcfDNA . 10%) with a Tacro trough below 6.8 mg/L. To assess the bias because of individual patients, a 100 · resampling of patient data was performed, 
Oellerich et al
where ;50% of patients were randomized into the dataset (5 or 6 per sampling). In each round, the best delimiter of Tacro concentration was calculated as above and recorded. The error was estimated with an SD of 0.4 mg/L (average: 6.9 mg/L), which suggests an influence of patients ,10%, for this consideration.
DISCUSSION
Circulating cell-free DNA is being used in a number of clinical settings to evaluate organ function and tumor growth, 11, [17] [18] [19] but most methods used previously have required either gender mismatch, expensive and time-consuming massive sequencing, or chip-based methods that require donor DNA to be available. The simplified GcfDNA method used here promises to be a practical, rapid, and relatively inexpensive way to directly interrogate the integrity of transplanted organs, such as livers. 12 Although the method cannot be used to examine the upper limit of the TR, these results do support the reports 4, 9, 10 that some currently used target trough Tacro concentrations are above what is required to maintain graft function in LTx patients. Our results using this novel method to interrogate organ integrity are consistent with the most recent report by Rodriquez-Peralvarez et al 9 who used traditional graft survival assessment, showing that trough Tacro concentrations as low as 7 mg/L are safe and effective in LTx patients. These authors reported that liver graft survival was better with a mean trough Tacro concentration of 7-10 mg/L compared with ,7 mg/L (P = 0.008) and 10-15 mg/L (P = 0.016). Tacro trough concentrations .7 mg/L on the day of protocol biopsy were associated with less moderate/severe rejection (23.8%) compared with ,7 mg/L (41.2%, P = 0.004). 9 Using the GcfDNA as a measure of graft integrity, we calculated a limit of 6.8 mg/L for the lower trough Tacro concentration, well in line with this observation in a large study group.
Taken together, these data suggest that GcfDNA can be used to establish effective concentrations for LTx patients. In addition, the method seems to be a useful way to measure individual responses to immunosuppressive therapy. For example, previously we observed rapid decreases in GcfDNA after the introduction of methylprednisolone. 12 As such, it has great potential for "personalized immunosuppression." Although studies with larger numbers and longer follow-up are needed, if these results are replicated and extended, GcfDNA could be used to select, adjust, minimize, or even discontinue certain immunosuppressant drugs in solid organ FIGURE 3. Receiver operator characteristic curve, with the putative lower limit of the TR of Tacro as delimiter (95% CI dashed). The group was divided into sample points with GcfDNA $10% versus ,10%. The fraction of sampling points with Tacro below a sliding delimiter in both groups was calculated for construction of the curve. Both the highest Youden index and the highest Fisher P were seen with a delimiter at 6.8 mg/L. Data points as given in Figure 1 were used. transplant patients. The timely and frequent application of this "liquid biopsy" could be especially useful to add some certainty about organ integrity during immunosuppressant drug minimization. This could help reduce both adverse drug events and rejection episodes by allowing clinicians to establish truly individualized minimal therapeutic targets rather than just unclear, broad population "ranges."
CONCLUSIONS
Serial measurements of GcfDNA and trough Tacro concentrations were used in a small number (n = 10) of adult LTx recipients to confirm what minimally effective Tacro concentrations are during the first 5-30 days after LTx. The minimally effective trough Tacro concentrations in all subjects in this small population seemed to be 6.8 mg/L. Direct measurement of graft integrity using GcfDNA can be used to establish minimally effective trough Tacro concentrations and probably other immunosuppressants for individual patients after solid organ transplantation.
